* Bionano Genomics Inc BNGO.OQ BNGO.O is expected
to show a
rise in quarterly revenue when it reports results on May 8 for
the period ending January 1 0001
* The San Diego California-based company is expected to
report a
14.5% increase in revenue to $8.492 million from $7.42 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.The company's guidance on March 5 2024, for the
period ended March 31, was for revenue between $8.25 million and
$8.75 million.
* LSEG's mean analyst estimate for Bionano Genomics Inc is
for a
loss of 64 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bionano
Genomics
Inc is $6.00, above its last closing price of $1.00.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.87
Jan. 1 2023 -0.92 -0.97 -1.00 Missed -3.1
Jan. 1 0001 -1.00 -1.03 -1.24 Missed -20
Mar. 31 2023 -1.10 -1.10 -1.20 Missed -9.1
Jan. -1.14 -1.10 -1.30 Missed -18.2
1 0001
Jan. 1 0001 -1.18 -1.15 -1.10 Beat 4.3
Jun. 30 2022 -1.03 -0.91 -1.10 Missed -20.4
Jan. 1 0001 -0.87 -0.75 -1.10 Missed -46.7
This summary was machine generated May 7 at 02:09 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)